Pricing

Vyne Therapeutics Inc (VYNE)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David Domzalski
Employees:
30
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER, NJ, 08807
800-775-7936
Stock Split History
DateRatio
2021-02-16 1:4
2023-02-13 1:18
VYNE Therapeutics Inc. focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the. treatment of moderate-to-severe acne vulgaris. FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial. for mild to moderate atopic dermatitis, is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available